Predicting Readmissions Using Omics, Biostatistical Evaluate and Artificial Intelligence
PROBE AI
1 other identifier
observational
500
1 country
1
Brief Summary
This study is a prospective registry that aims to predict readmissions in patients with heart failure, using -omics, machine learning, patient reported outcomes, clinical data and other high-dimensional data sources.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2019
CompletedFirst Submitted
Initial submission to the registry
August 25, 2021
CompletedFirst Posted
Study publicly available on registry
August 31, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2029
ExpectedSeptember 2, 2021
August 1, 2021
5.7 years
August 25, 2021
August 30, 2021
Conditions
Outcome Measures
Primary Outcomes (2)
Cardiovascular readmission
Non-elective readmission to hospital for a cardiovascular cause
30 day
Heart failure readmission
Non-elective readmission to hospital for heart failure
30 day
Secondary Outcomes (3)
Mortality
30-day
Cardiovascular death
30-day
All-cause readmission
30-day
Study Arms (1)
Hospitalized heart failure cohort
Patients hospitalized with heart failure
Interventions
Eligibility Criteria
Hospitalized heart failure patients
You may qualify if:
- Any patient aged 18 years or older admitted to hospital or seen in the emergency department with heart failure defined clinically
- The diagnosis will be guided by the Framingham criteria for HF and/or BNP. A BNP \>400 will be defined as definite heart failure and BNP 100-400 classified as possible heart failure.
- Provides informed consent
You may not qualify if:
- Patients who cannot communicate due to dementia or severe cognitive deficits
- non-Ontario residents
- nursing home residents
- those who are not discharged home but are discharged to a skilled nursing facility (long-term care or chronic institution)
- those who are unable to communicate who do not have a proxy (e.g. spouse or close family member) to facilitate communication with the patient.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Institute for Clinical Evaluative Scienceslead
- Ted Rogers Centre for Heart Researchcollaborator
- Peter Munk Cardiac Centrecollaborator
- Vector Institute for Artificial Intelligencecollaborator
Study Sites (1)
University Health Network
Toronto, Ontario, Canada
Biospecimen
Blood samples are stored in a biobank
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Senior Scientist
Study Record Dates
First Submitted
August 25, 2021
First Posted
August 31, 2021
Study Start
February 1, 2019
Primary Completion
September 30, 2024
Study Completion (Estimated)
September 30, 2029
Last Updated
September 2, 2021
Record last verified: 2021-08
Data Sharing
- IPD Sharing
- Will not share